(Clazakizumab)Biosimilar Reference Antibody-GS40137 新品

货号：GS40137

Clazakizumab is an investigational fully human monoclonal antibody developed as a targeted therapy for antibody-mediated rejection (AMR) in organ transplant recipients, particularly those who have undergone kidney transplantation. It is designed to modulate a specific inflammatory pathway that drives the immune system's attack against the transplanted organ. Clinical trials are evaluating its efficacy in treating chronic active AMR, a condition with limited therapeutic options that often leads to graft loss. The drug has received Breakthrough Therapy Designation from the U.S. FDA for this indication, highlighting its potential to address a serious unmet medical need.